Evaxion A/S (EVAX) vs TransCode Therapeutics (RNAZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Evaxion A/S (EVAX) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 51.5% versus a loss of 88.4%. Over five years, EVAX leads with a -99.2% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($29.0 million vs $27.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | EVAX | RNAZ |
|---|---|---|
| Share price | $3.05 | $1.71 |
| Market cap | $27.52M | $28.95M |
| 1-day change | -2.87% | -2.84% |
| YTD return | -36.06% | -74.96% |
| 1-year return | -51.51% | -88.45% |
| 5-year return | -99.23% | -100.00% |
| EPS (TTM) | $-1.00 | $-52.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.15 | $15.94 |
| 52-week low | $2.77 | $1.52 |
| Distance from 52-week high | -74.90% | -89.27% |
| Analyst consensus | none | — |
| Avg. price target upside | +268.85% | — |
| Average volume | 200.14K | 50.19K |
| Shares outstanding | 9.02M | 16.93M |
| Employees | 46 | 12 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EVAX has outperformed RNAZ by 36.9 percentage points over the past year.
About Evaxion A/S
EVAX stock →Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia.
Healthcare · Biotechnology · 46 employees
About TransCode Therapeutics
RNAZ stock →TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.
Healthcare · Biotechnology · 12 employees
EVAX vs RNAZ FAQ
Which is bigger, Evaxion A/S or TransCode Therapeutics?
TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $28.95M compared with $27.52M for Evaxion A/S (EVAX).
Which stock has performed better over the past year, EVAX or RNAZ?
EVAX returned -51.51% over the past 12 months, compared with -88.45% for RNAZ (price return, excluding dividends). Past performance does not predict future results.
Are Evaxion A/S and TransCode Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.